SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 200.79-0.2%Nov 14 9:30 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Henry Niman who wrote (14921)2/12/1998 7:30:00 PM
From: Flagrante Delictu  Read Replies (2) of 32384
 
Henry, << CNTO paid Roche $350 million for a cancer drug.>> That would amount to approximately $7.00 per share on LGND's approximately 50 million fully diluted shares. LGND announced at various bio conferences that the have 75 key IR targets, many of which are proprietary to LGND & another 2 dozen STAT's targets. One can see, in the light of this CNTO purchase , why DR has publicly stated that LGND has built substantial unrecognized {by Wall St.} value for its' shareholders. Makes one wonder if we sold too cheaply to LLY. Even if so, there could be plenty of unrecognized value left. Bernie
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext